Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
44M people world wide
...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included.

44M people world wide


-
...TBI increases risk of dementia by as much as two-fold
  
44M people world wide
44M People World Wide

...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included...

Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

 

News & Events 2008 - 2009

 

 

September 29, 2009: ALSP's Principle Investigator, Dr. Greg Hook, awarded an American Recovery and Reinvestment Act of 2009 supplemental grant award 3R44AG030865-02S1 for hiring a post-doctoral fellow to develop protease inhibitor drugs to treat Alzheimer's disease Read More...

 

August 16, 2009: Dr. Gregory Einhorn joins ALSP Inc. as in-house Patent Counsel.



August 1, 2009: Dr. Nancy Sipes joins ALSP Inc. as VP of Product Development.


July 9, 2009: ALSP's lead compound admitted to the Investigative New Drug (IND) enabling toxicology contract program sponsored by the National Institute on Aging (NIA) in the National Institutes of Health (NIH), Bethesda, MD, conducted at SRI International, Menlo Park, CA, for promising Alzheimer's Disease therapeutics.

Read More...

 

January 30, 2009: ALSP's Principle Investigator Dr. Greg Hook awarded grant 1R21AG031963 from the National Institute on Aging (NIA) in the National Institute of Health (NIH), Bethesda, MD, to develop new prodrugs to treat Alzheimer's Disease.

 

November 14, 2008: ALSP's Principle Investigator, Dr. Greg Hook, awarded fast-track Small Business Innovative Research (SBIR) grant 1R44AG030865 from the National Institute on Aging (NIA) in the National Institute of Health (NIH), Bethesda, MD, to develop protease inhibitor drugs to treat Alzheimer's disease.

 

November 3, 2008: ALSP's Principle Investigator, Dr. Greg Hook, awarded fast-track Small Business Innovative Research (SBIR) grant 1R44AG032784 from the National Institute on Aging (NIA) in the National Institute on Health (NIH), Bethesda, MD, to develop E64d to treat Alzheimer's Disease.


March 18, 2008: Potential Alzheimer's Disease Drug Target Identified

Read More...


< Back